EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical Characteristics and Outcome of Diffuse Large B-Cell Lymphoma: Real-World Data From Saudi Arabia

Abdullah M Alrajhi, Tariq AlQahtani, Jude Howaidi iD, Muhnad AlHumaid, Batool Sharbek, Aysha Masri, Arwa AlHaj Issa iD, Amal AlOtaibi iD, Raghad Saleh Alajmi iD, Ruyuf Abdullah Alshuqayr, Sadeem Abdulaziz Alamri iD, Mohsen Alzahrani iD und 2 weitere

JCO Global Oncology · 2026-04 · 12 (4)

DOI: 10.1200/go-25-00432 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2026-04. Verfasst von Abdullah M Alrajhi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, AlFaisal University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma worldwide and in Saudi Arabia. However, regional data on clinical characteristics and outcomes remain limited. METHODS This multicenter retrospective cohort study included 516 patients age ≥14 years diagnosed with DLBCL between January 2016 and December 2023 at two tertiary hospitals in Saudi Arabia. Data on demographics, disease features, treatment, and outcomes were collected. Survival analysis was performed using Kaplan-Meier and Cox regression models. RESULTS The median age at diagnosis was 60.5 years, with 53% of patients younger than 65 years. Most patients (77%) had advanced-stage disease. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone was the most commonly used first-line regimen, particularly in younger patients (95% v 62%). Complete remission rates were 74% in patients younger than 65 years and 66% in those 65 years and older ( P = .09). Relapse or refractory disease occurred more frequently in older patients (40% v 27%, P = .0019). Two-year progression-free survival was 78% in younger patients and 64% in older patients ( P = .004), while 2-year overall survival (OS) was 87% and 76%, respectively ( P = .001). Age, performance status, comorbidities, MYC expression, and kidney involvement were significant predictors of OS. CONCLUSION This study provides valuable real-world insight into the clinical landscape of DLBCL in Saudi Arabia. Overall outcomes are consistent with international data, although older age and comorbidities remain associated with poorer prognosis. As advanced therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies become more available, further improvements in survival are expected. These findings underscore the need for a national lymphoma registry and continued investment in research infrastructure to guide evidence-based, personalized care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsHumansSaudi ArabiaFemaleRetrospective StudiesMiddle AgedMaleAgedAdultPrednisoneDoxorubicinCyclophosphamideVincristine

Substanzen

PrednisoneDoxorubicinCyclophosphamideVincristine

Autor:innen und Institutionen

  • Department of Pharmacy Practice, College of Pharmacy, AlFaisal University, Riyadh, Saudi Arabia.
  • Clinical Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia.
  • Department of Pharmacy, Oncoclinicas, Riyadh, Saudi Arabia.
  • Department of Preclinical Studies, Benefit and Risk Assessment Executive Directorate, Drug Sector-Saudi Food and Drug Authority, Riyadh, Saudi Arabia.
  • Adult Hematology and Bone Marrow Transplant Department, King Fahad Medical City, Riyadh, Saudi Arabia.
  • Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

ORCID-Profile: Jude Howaidi, Arwa AlHaj Issa, Amal AlOtaibi, Raghad Saleh Alajmi, Sadeem Abdulaziz Alamri, Mohsen Alzahrani, Ahmed S Alaskar, Nada Alsuhebany

Zitieren

APA

Alrajhi, A. M., AlQahtani, T., Howaidi, J., AlHumaid, M., Sharbek, B., Masri, A., Issa, A. A., AlOtaibi, A., Alajmi, R. S., Alshuqayr, R. A., Alamri, S. A., Alzahrani, M., Alaskar, A. S., & Alsuhebany, N. (2026). Clinical Characteristics and Outcome of Diffuse Large B-Cell Lymphoma: Real-World Data From Saudi Arabia. JCO Global Oncology, 12(4). https://doi.org/10.1200/go-25-00432

Vancouver

Alrajhi AM, AlQahtani T, Howaidi J, AlHumaid M, Sharbek B, Masri A, et al. Clinical Characteristics and Outcome of Diffuse Large B-Cell Lymphoma: Real-World Data From Saudi Arabia. JCO Global Oncology. 2026;12(4). doi:10.1200/go-25-00432

BibTeX
@article{Alrajhi2026,
  author = {Alrajhi, Abdullah M and AlQahtani, Tariq and Howaidi, Jude and AlHumaid, Muhnad and Sharbek, Batool and Masri, Aysha and Issa, Arwa AlHaj and AlOtaibi, Amal and Alajmi, Raghad Saleh and Alshuqayr, Ruyuf Abdullah and Alamri, Sadeem Abdulaziz and Alzahrani, Mohsen and Alaskar, Ahmed S and Alsuhebany, Nada},
  title = {Clinical Characteristics and Outcome of Diffuse Large B-Cell Lymphoma: Real-World Data From Saudi Arabia},
  journal = {JCO Global Oncology},
  year = {2026},
  volume = {12},
  number = {4},
  doi = {10.1200/go-25-00432}
}
Kostenlos starten →